COVID-19: India becomes third country to cross 3 lakh deaths
India has crossed the three lakh mark count in deaths making it the third nation after the US, Brazil.
On Monday morning, India has become the third country after Brazil and the United States to record over 3 lakh deaths linked to the Coronavirus since the pandemic broke. The death toll has reached 303,720 after 4,454 people succumbed to Covid-19 in the last 24 hours, reported the Union ministry of health and family welfare (MoHFW)
India registered more than 3 lakh COVID19 recoveries in the last 24 hours. The number of people who have recovered from the disease surged to 2,37,28,011, while the case fatality rate has increased to 1.14 percent, the data stated.
“#CoronaVirusUpdates: 📍#COVID19 India Tracker (As on 24 May, 2021, 08:00 AM) ➡️Confirmed cases: 2,67,52,447 ➡️Recovered: 2,37,28,011 (88.69%)👍 ➡️Active cases: 27,20,716 (10.17%) ➡️Deaths: 3,03,720 (1.14%) #IndiaFightsCorona #Unite2FightCorona #StaySafe @MoHFW_INDIA,” tweeted the official handle of Official Government of India updates on COVID19 by MIB India.
Check it out:
📍#COVID19 India Tracker
(As on 24 May, 2021, 08:00 AM)➡️Confirmed cases: 2,67,52,447
➡️Recovered: 2,37,28,011 (88.69%)👍
➡️Active cases: 27,20,716 (10.17%)
➡️Deaths: 3,03,720 (1.14%)#IndiaFightsCorona#Unite2FightCorona#StaySafe @MoHFW_INDIA pic.twitter.com/Gp17XXfwm0— #IndiaFightsCorona (@COVIDNewsByMIB) May 24, 2021
However, fresh infections went down to 2,22,315, the lowest since April 15. Tamil Nadu continues to be the top contributor with 35,483 new cases. While Maharashtra reported 26,672 cases, Karnataka’s number stood at 25,979.
Black Fungus or Mucormycosis in Covid patients has emerged as a big concern in India’s fight against coronavirus.
The company’s Business Development and International Advocacy Head Dr. Raches Ella on Sunday said Bharat Biotech may begin pediatric trials of its Covid-19 vaccine Covaxin from June.
Stay tuned to The Live Mirror for more updates.
ALSO READ: COVID-19: Maharashtra Suspends Vaccination Drive For 18-44 Age Group